Tiger Brokers

BUZZ-Bluebird falls as FDA weighs cancer risks of co's gene therapy

Reuters
Nov 28, 2024
BUZZ-Bluebird falls as FDA weighs cancer risks of co's gene therapy

** Shares of gene therapy developer bluebird bio BLUE.O fall 1.8% to 36 cents; set to snap a three-day winning streak

** The U.S. FDA says it is weighing the need of regulatory action on BLUE's gene therapy, Skysona, used to treat a rare neurological disorder called cerebral adrenoleukodystrophy

** Additional cases of serious blood cancers reported in patients treated with Skysona, FDA says; therapy's prescribing information already warns of those risks

** FDA advises exploring alternative therapies before using Skysona, considering the risk of blood cancers

** Including session's gains, stock has fallen 73.6% YTD and has been trading below the $1-mark since mid-August

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10